The Longer, the Better: Continuous Glucose Monitoring Use for ≥90% Is Superior to 70%-89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes.

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes technology & therapeutics Pub Date : 2025-01-06 DOI:10.1089/dia.2024.0472
Alzbeta Santova, Vit Neuman, Lukas Plachy, Shenali Anne Amaratunga, Marketa Pavlikova, Martina Romanova, Petra Konecna, David Neumann, Kamila Kocourkova, Jiri Strnadel, Renata Pomahacova, Petra Venhacova, Jaroslav Skvor, Barbora Obermannova, Stepanka Pruhova, Ondrej Cinek, Zdenek Sumnik
{"title":"The Longer, the Better: Continuous Glucose Monitoring Use for ≥90% Is Superior to 70%-89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes.","authors":"Alzbeta Santova, Vit Neuman, Lukas Plachy, Shenali Anne Amaratunga, Marketa Pavlikova, Martina Romanova, Petra Konecna, David Neumann, Kamila Kocourkova, Jiri Strnadel, Renata Pomahacova, Petra Venhacova, Jaroslav Skvor, Barbora Obermannova, Stepanka Pruhova, Ondrej Cinek, Zdenek Sumnik","doi":"10.1089/dia.2024.0472","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> The recommended threshold for the time spent on continuous glucose monitoring (CGM) is established at 70%. However, glucose outcomes in children with type 1 diabetes (CwD) using CGM for a different proportion of time within this threshold have not been evaluated yet. The study aims to compare glycemic parameters among CwD who spent 70%-89% and ≥90% on CGM using the population-wide data from the Czech national pediatric diabetes registry ČENDA. <b><i>Methods:</i></b> CwD aged <19 years who used real-time CGM >70% of the time and did not change the type of therapy throughout the year 2023 were included and divided into two groups based on the time they spent on CGM-70%-89% versus ≥90%. HbA1c, times in standard glycemic ranges, mean glucose, and coefficient of variability (CV) were compared between the groups and by treatment modalities. <b><i>Results:</i></b> Data from 1977 CwD (1035 males and 942 females) were evaluated. Among them, 404 participants (20.4%) used CGM 70%-89% of the time, and 1573 participants (79.6%) ≥90% of the time. Compared with the 70-89% group, the ≥90% CGM users achieved significantly lower HbA1c levels (51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, <i>P</i> < 0.001), higher time in range (72% vs. 60%, <i>P</i> < 0.001), and lower mean glucose and CV (8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL and 37% vs. 40%, respectively, both <i>P</i> < 0.001). Analogous results were seen irrespective of the treatment modality. The differences persisted after propensity score adjustment. <b><i>Conclusion:</i></b> CGM use for ≥90% is associated with tighter glycemic control compared with 70%-89% use. Therefore, it is essential to motivate CwD to use CGM for the longest possible time and search for suitable options to overcome barriers in uninterrupted CGM monitoring.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2024.0472","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The recommended threshold for the time spent on continuous glucose monitoring (CGM) is established at 70%. However, glucose outcomes in children with type 1 diabetes (CwD) using CGM for a different proportion of time within this threshold have not been evaluated yet. The study aims to compare glycemic parameters among CwD who spent 70%-89% and ≥90% on CGM using the population-wide data from the Czech national pediatric diabetes registry ČENDA. Methods: CwD aged <19 years who used real-time CGM >70% of the time and did not change the type of therapy throughout the year 2023 were included and divided into two groups based on the time they spent on CGM-70%-89% versus ≥90%. HbA1c, times in standard glycemic ranges, mean glucose, and coefficient of variability (CV) were compared between the groups and by treatment modalities. Results: Data from 1977 CwD (1035 males and 942 females) were evaluated. Among them, 404 participants (20.4%) used CGM 70%-89% of the time, and 1573 participants (79.6%) ≥90% of the time. Compared with the 70-89% group, the ≥90% CGM users achieved significantly lower HbA1c levels (51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, P < 0.001), higher time in range (72% vs. 60%, P < 0.001), and lower mean glucose and CV (8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL and 37% vs. 40%, respectively, both P < 0.001). Analogous results were seen irrespective of the treatment modality. The differences persisted after propensity score adjustment. Conclusion: CGM use for ≥90% is associated with tighter glycemic control compared with 70%-89% use. Therefore, it is essential to motivate CwD to use CGM for the longest possible time and search for suitable options to overcome barriers in uninterrupted CGM monitoring.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
时间越长越好:在1型糖尿病儿童中,持续血糖监测使用率≥90%优于70%-89%。
目的:建议持续血糖监测(CGM)时间阈值为70%。然而,在该阈值内使用CGM的不同时间比例的1型糖尿病儿童(CwD)的血糖结局尚未得到评估。该研究的目的是比较在CGM上花费70%-89%和≥90%的CwD的血糖参数,使用捷克国家儿科糖尿病登记处ČENDA的全人群数据。方法:纳入2023年全年70%的年龄且未改变治疗类型的CwD,并根据他们在cgm上花费的时间分为70%-89%和≥90%两组。比较各组和不同治疗方式的HbA1c、标准血糖范围次数、平均血糖和变异系数(CV)。结果:对1977例CwD患者(男性1035例,女性942例)的资料进行了评价。其中404人(20.4%)使用CGM的时间为70% ~ 89%,1573人(79.6%)≥90%。与70-89%组相比,≥90% CGM使用者的HbA1c水平显著降低(51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, P < 0.001),持续时间延长(72% vs. 60%, P < 0.001),平均葡萄糖和CV降低(分别为8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL和37% vs. 40%,均P < 0.001)。无论治疗方式如何,都可以看到类似的结果。倾向得分调整后差异依然存在。结论:与70%-89%的使用相比,使用≥90%的CGM与更严格的血糖控制相关。因此,必须鼓励CwD尽可能长时间地使用CGM,并寻找合适的选择来克服不间断CGM监测中的障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
期刊最新文献
Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial. The Association of Time-in-Range and Time-in-Tight-Range with Retinopathy Progression in the Virtual Diabetes Control and Complications Trial Continuous Glucose Monitoring Dataset. A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes. FRONTIER-FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database-Evidence from Real-World Practice: Patients Using Intensive Insulin. Omnipod5 Real-World Data from the First Pediatric Users' Universal Coverage Under the UK National Health Service.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1